.png){kind=small}
Stabilizing the Nervous System.
Personalizing the Taper.
Understanding Benzodiazepine Withdrawal
A broader view of overlapping and multidimensional symptom patterns.
Our earlier preprint used a rule-based framework to organize symptom reports. Our ongoing work examines these categories as exploratory clinical summaries rather than fixed patient types and further evaluates overlapping symptom organization.
Broad Overlapping Symptom Patterns
Benzodiazepine withdrawal is often experienced as complex and unpredictable.
Our research examines the broad, overlapping, and multidimensional nature of withdrawal symptoms.
In an observational cohort of 39 patients, we studied symptom burden across 233 symptom items. Building on this work, we developed a structured ontology that organizes withdrawal symptoms across multiple, overlapping areas of brain–body regulation.
The findings suggest that withdrawal is not adequately described by a single symptom, mechanism, or fixed category. Instead, patients experience different combinations and levels of symptom burden across several areas of function.
This broader view may help improve symptom description, clinical communication, and future research—and highlights why withdrawal care should consider more than taper speed or anxiety alone.
The Five Axes of Withdrawal
The Five-Axis Stress Biology Framework™ is a clinician-developed model for organizing broad, overlapping categories of symptoms reported during benzodiazepine withdrawal.
The framework supports education, clinical description, and future research. It does not assign patients to fixed categories or determine the biological cause of an individual symptom.
Axis 1 — CRH/Adrenergic Stress
Threat, arousal, sleep disruption, and stress-system symptoms
This domain includes symptoms such as panic, hypervigilance, internal tremor, morning surges, and sleep disruption. Stress and adrenergic signaling are possible areas of biological relevance.
Axis 2 — Excitatory–Neuroinflammatory
Sensory amplification, pain, fatigue, and cognitive symptoms
This domain includes symptoms such as burning sensations, head pressure, sensory overload, fatigue, and cognitive slowing. Altered excitatory and neuroimmune regulation are possible areas for further study.
Axis 3 — Autonomic
Heart rate, blood pressure, digestion, temperature, and exertional symptoms
This domain includes symptoms involving heart rate or blood pressure, orthostatic intolerance, gastrointestinal function, temperature regulation, and exertional intolerance. These symptoms may resemble autonomic dysfunction but do not by themselves establish a diagnosis of dysautonomia.
Axis 4 — Basal Ganglia–Cerebellar Motor
Movement, restlessness, balance, and coordination symptoms
This domain includes akathisia-like restlessness, tremor-like sensations, disequilibrium, and difficulties with movement, balance, or coordination. Motor-control and sensory-gating mechanisms are possible areas for further study.
Axis 5 — Neuroimmune/Visceral Regulation
Immune-related, histamine-like, and visceral-regulatory symptoms
This domain includes immune-related and visceral-regulatory symptoms. Mast-cell- or histamine-related features are tracked as a cross-cutting feature that can accompany any of the other axes, rather than as a separate axis. This domain is used descriptively and does not establish a diagnosis of mast-cell activation syndrome.
The Five-Axis Framework provides a broad clinical and educational overview, while our newer ontology research provides a more detailed representation of symptoms across multiple overlapping regulatory systems. The published analysis used the study's original domain labels — CRH/Adrenergic, Excitatory/Neuroinflammatory, Autonomic, Basal Ganglia–Cerebellar, and MCAS-overlap — which define the item groupings on which that analysis was performed. The framework names used here reflect later clinical refinement of the same five domains.
What the Analyses Found
Patient-reported benzodiazepine-withdrawal symptoms spanned many areas of experience, including mood and arousal, sensory and bodily sensations, cognition, sleep, movement, autonomic function, and changes in the sense of self or surroundings.
Symptom burden varied substantially across patients. Different individuals experienced different combinations, intensities, and levels of functional impact.
Our provisional ontology analysis indicates that many symptom concepts map to more than one area of brain–body regulation. This overlapping structure may help explain why withdrawal can feel multisystem and difficult to describe using a single symptom category.
Overall, the findings support viewing benzodiazepine withdrawal as broad and multidimensional rather than reducing patients to a single fixed type.
These findings support looking beyond dose alone and considering the patient’s broader symptom burden, stability, functioning, and response over time.
Dysautonomia International 2026 Posters
Autonomic-type symptoms can occur during benzodiazepine withdrawal and may involve heart rate or blood pressure, digestion, breathing, temperature regulation, and exertional tolerance.
These findings were presented in two posters at the Dysautonomia International meeting in July 2026.
The posters linked below are updated versions that reflect our current interpretation of the data, emphasizing broad, overlapping symptom organization.
Educational Lecture
The Five-Axis Stress Biology Framework
Public educational talk. Not medical advice.
Beyond Dose Reduction: Understanding the Broader Context of Withdrawal
This work was initially reported by Dr. Madhava in the 2025 medRxiv preprint, “Benzodiazepine Withdrawal Symptom Clusters: Distinct Phenotypes with Treatment Implications.” (doi:10.1101/2025.10.07.25336923)
The analysis presented on this page reflects our current interpretation of the findings.
Benzodiazepine discontinuation is often approached primarily as a dosing problem. Gradual, individualized tapering remains essential, but dose reduction alone does not explain the full withdrawal experience.
Patients may respond differently even when following similar taper schedules. Sleep, stress, illness, activity, overstimulation, medication changes, relevant medical conditions, and previous responses to dose reductions may all influence stability and taper tolerance.
Our research examines withdrawal as a broad, overlapping, and multidimensional symptom experience. The findings support considering not only dose and taper speed, but also symptom burden, daily functioning, current stability, and changes over time.
What This Means for Care
The Five-Axis Stress Biology Framework™ provides a clinical and educational way to organize complex withdrawal symptoms, while our newer ontology research examines how symptoms extend across multiple, overlapping areas of brain–body regulation.
In clinical practice, care remains individualized and may include taper adjustment, stabilization of sleep and routines, pacing, reduction of overstimulation, symptom-specific support, and evaluation of relevant medical or psychiatric conditions. Decisions are guided by the patient’s overall stability, functioning, symptom burden, and response to previous changes—not by a generic schedule or fixed category.
Effective tapering requires attention to the whole clinical picture—not dose alone.
This link opens the currently available preprint.